TFF Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
TFF Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q3 2024.
  • TFF Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 58.2 %, a 606% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 58.2 +50 +606% Sep 30, 2024
Q2 2024 32.4 +23.2 +253% Jun 30, 2024
Q1 2024 21.6 +10.4 +93.5% Mar 31, 2024
Q4 2023 12.7 +2.72 +27.3% Dec 31, 2023
Q3 2023 8.24 -0.96 -10.4% Sep 30, 2023
Q2 2023 9.18 +2.36 +34.6% Jun 30, 2023
Q1 2023 11.2 +6.99 +167% Mar 31, 2023
Q4 2022 9.97 +6.57 +193% Dec 31, 2022
Q3 2022 9.21 +6.09 +196% Sep 30, 2022
Q2 2022 6.82 +3.6 +112% Jun 30, 2022
Q1 2022 4.17 +0.8 +23.7% Mar 31, 2022
Q4 2021 3.41 -0.39 -10.3% Dec 31, 2021
Q3 2021 3.11 -1.19 -27.7% Sep 30, 2021
Q2 2021 3.22 -5.57 -63.4% Jun 30, 2021
Q1 2021 3.37 Mar 31, 2021
Q4 2020 3.8 Dec 31, 2020
Q3 2020 4.3 Sep 30, 2020
Q2 2020 8.79 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.